<DOC>
	<DOC>NCT02916446</DOC>
	<brief_summary>This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.</brief_summary>
	<brief_title>Safety Study of Viaskin Peanut to Treat Peanut Allergy</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Physiciandiagnosed peanut allergy; A peanut Skin Prick Test (SPT) with a wheal largest diameter ≥8 mm; A specificpeanut Immunoglobulin E (IgE) ≥14 kU/L; Subjects following a strict peanutfree diet. Generalized dermatologic disease Spirometry forced expiratory volume in 1 second (FEV1) &lt;80% of the predicted value, or peak expiratory flow (PEF) &lt;80% of predicted value; Receiving βblocking agents, angiotensinconverting enzyme inhibitors, angiotensinreceptor blockers, calcium channel blockers or tricyclic antidepressant therapy; antitumor necrosis factor drugs or antiIgE drugs (such as omalizumab) or any biologic immunomodulatory therapy; Prior or concomitant history of any immunotherapy to any food allergy (for example EPIT, OIT, SLIT, or specific oral tolerance induction).</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>